NAD+: Research Overview, Mechanisms, and Current Evidence
NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme present in every cell, central to energy metabolism, DNA repair, and the activity of enzymes such as sirtuins. Cellular NAD+ levels are reported to decline with age, which has driven research into ways to restore them. Most controlled human studies use oral NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) rather than NAD+ itself. The information below summarizes published research for educational and research purposes only. It is not medical advice and is not guidance for use in humans.
Available for research use from our preferred vendor, Project Zero. For laboratory research use only.
How It Works (Preclinical Mechanisms)
NAD+ functions as a central coenzyme in metabolism. Research has focused on how raising NAD+ levels, usually through precursors, affects cellular pathways linked to energy and aging.
- Acts as an electron carrier in cellular respiration, central to converting nutrients into usable energy.
- Serves as a required substrate for sirtuins and PARP enzymes involved in DNA repair and gene regulation.
- Reported to decline with age, with research examining whether precursor supplementation can restore levels.
- Studied for downstream effects on mitochondrial function and metabolic markers in animal and human work.
Areas of Research Interest
Published studies have examined NAD+ and its precursors in the following research contexts. Much of the strongest human evidence involves the precursors NR and NMN.
Aging and longevity
Studied for whether restoring NAD+ levels affects markers associated with biological aging.
Muscle and physical function
Investigated in trials of NMN and NR for effects on muscle function and walking performance in older adults.
Metabolic health
Examined for effects on insulin resistance, liver enzymes, and blood pressure in middle-aged and older adults.
Menopause and hormonal health
Studied in pilot work for effects on menopausal symptoms and estrogen-related markers.
Reported Study Parameters
For laboratory research use only. The table below reports the doses and routes used in specific published studies, with sources. It describes what researchers administered in these models and is not a protocol, recommendation, or guidance for use in humans or animals. Most controlled human evidence involves oral NAD+ precursors rather than NAD+ itself.
| Research Model | Dose and Route Reported | Source |
|---|---|---|
| Middle-aged and older adults, hypertension (RCT, NR precursor) | Nicotinamide riboside 1000 mg per day, oral, for 6 weeks | Lin 2025·DOI |
| Healthy adults 40 to 65 (RCT, NMN precursor) | Nicotinamide mononucleotide 300, 600, or 900 mg per day, oral, for 60 days; dose-dependent rise in blood NAD+ | Kuerec 2024·DOI |
| Human research | Direct NAD+ has limited controlled-trial evidence; most human data come from oral precursors (NR, NMN) that raise NAD+ levels | Wang 2025·DOI |
Products are supplied as lyophilized powder requiring reconstitution. For reconstitution concentration math, use the Peptide Calculator.
Latest Research (2024 to 2026)
Recent peer-reviewed literature indexed on PubMed continues to test NAD+ precursors in humans, with results that are promising in some areas and inconclusive in others.
Menopausal symptoms (pilot trial)
A 2026 open-label pilot trial reported that 7 days of a nicotinamide riboside plus pterostilbene combination reduced the frequency and severity of bloating, hot flashes, and poor sleep and raised the estradiol to estrone ratio in symptomatic women. PubMed·DOI
Blood pressure and exercise (RCT)
A 2025 pilot randomized trial reported that nicotinamide riboside at 1000 mg per day combined with walking exercise was not superior to placebo plus exercise for lowering daytime blood pressure, though trends toward nighttime reductions were noted. PubMed·DOI
Muscle and liver function (meta-analysis)
A 2025 systematic review and meta-analysis of randomized trials reported that NMN supplementation had significant effects on gait speed and liver enzyme (ALT) levels in middle-aged and elderly individuals, supporting further study. PubMed·DOI
Personalized NMN dosing
A 2024 analysis of a double-blind trial reported a dose-dependent rise in blood NAD+ with NMN at 300, 600, or 900 mg per day over 60 days, alongside high variability between individuals, supporting NAD+ monitoring to tailor dosing. PubMed·DOI
Research Questions
What is NAD+?
NAD+ is a coenzyme found in all living cells that is essential for energy metabolism, DNA repair, and the activity of enzymes such as sirtuins. Its levels are reported to fall with age.
Why do studies often use precursors instead of NAD+?
Most controlled human studies use oral precursors such as NR and NMN, which reliably raise blood NAD+ levels. Direct NAD+ has comparatively limited controlled-trial evidence.
What does the available evidence suggest?
Precursor trials show that NAD+ levels can be raised and report some functional signals, but results are mixed and no NAD+-raising product is approved to treat a disease. The area remains under active investigation.
Referenced Citations
Literature indexed on PubMed.
- Holmes, H.E., et al. (2026). Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial. Front. Aging, 7, 1773667. PubMed·DOI
- Lin, Y., et al. (2025). Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial. GeroScience, 47(6), 6895-6908. PubMed·DOI
- Wang, J.P., et al. (2025). Effects of nicotinamide mononucleotide supplementation on muscle and liver functions among the middle-aged and elderly: a systematic review and meta-analysis of randomized controlled trials. Curr. Pharm. Biotechnol., 26(13), 2141-2152. PubMed·DOI
- Kuerec, A.H., et al. (2024). Towards personalized nicotinamide mononucleotide (NMN) supplementation: nicotinamide adenine dinucleotide (NAD) concentration. Mech. Ageing Dev., 218, 111917. PubMed·DOI
PeptideInfo.org provides information strictly for educational and research purposes. All referenced products are intended for laboratory and research use only and are not approved for human consumption, medical use, or self-administration. Nothing on this page constitutes medical advice. Research summaries reference literature indexed on PubMed.